Huadong Medicine Company

Chongqing Yuyan is a biomedical innovation and medical beauty product research and development company. It intends to address the biosafety concerns associated with extracting natural botulinum toxin from the host Clostridium botulinum.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, specializing in oncology and the development of antibody drug conjugates (ADCs). The company focuses on advancing its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform, with key candidates including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Additionally, Heidelberg Pharma is engaged in developing MGTA-XX-ATACs for hematopoietic stem cells, as well as conditioning programs for blood cancers and genetic diseases. The company also provides preclinical research services related to cancer and inflammatory and autoimmune diseases. Founded in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG rebranded in October 2017 and continues to serve the pharmaceutical and biotechnology industries through various research and development services.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, specializing in oncology and the development of antibody drug conjugates (ADCs). The company focuses on advancing its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform, with key candidates including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Additionally, Heidelberg Pharma is engaged in developing MGTA-XX-ATACs for hematopoietic stem cells, as well as conditioning programs for blood cancers and genetic diseases. The company also provides preclinical research services related to cancer and inflammatory and autoimmune diseases. Founded in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG rebranded in October 2017 and continues to serve the pharmaceutical and biotechnology industries through various research and development services.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, specializing in oncology and the development of antibody drug conjugates (ADCs). The company focuses on advancing its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform, with key candidates including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Additionally, Heidelberg Pharma is engaged in developing MGTA-XX-ATACs for hematopoietic stem cells, as well as conditioning programs for blood cancers and genetic diseases. The company also provides preclinical research services related to cancer and inflammatory and autoimmune diseases. Founded in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG rebranded in October 2017 and continues to serve the pharmaceutical and biotechnology industries through various research and development services.

Ashvattha Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products that address unmet medical needs in neurology, oncology, and ophthalmology, as well as inflammatory diseases. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These innovative therapies are designed to selectively target actively endocytosing cells, such as reactive microglia and macrophages, which play significant roles in chronic inflammation and disease progression. By improving precision targeting, Ashvattha aims to minimize off-target toxicity, systemic side effects, and immunogenicity commonly associated with other therapeutic platforms. The company currently has a pipeline of nine therapeutics under development, focusing on enhancing treatment efficacy while reducing adverse effects for patients.

R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

Ningbo Donghai Bank offers services for business banking. They collaborate with the corporate culture of implementing sunshine management, forming a sunshine team and business, offering a sunshine service, and creating a sunny brand. They aim to create a business with qualities, values, and compassion a regional bank an enhanced service provider; to make appropriate contributions to the high-quality development of the regional economy and society, and to continuously embark on new endeavors.